ATRICURE INC (ATRC)
US04963C2098 - Common Stock
First Week of June 21st Options Trading For AtriCure (ATRC)
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
RSI Alert: AtriCure (ATRC) Now Oversold
AtriCure to Announce First Quarter 2024 Financial Results
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
AtriCure Enters Oversold Territory (ATRC)
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
First Week of March 15th Options Trading For AtriCure (ATRC)
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024
AtriCure Appoints Shlomi Nachman to the Board of Directors
AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
First Week of ATRC July 2024 Options Trading
AtriCure stock defended at UBS despite Medtronic's rival
AtriCure (ATRC) stock gained Wednesdays after UBS defended it despite a market entry of Medtronic's (MDT) rival product to company's AtriClip device. Read more here.
Needham says Medtronic could create overhang on AtriCure shares (ATRC)
Needham said it was maintaining its buy rating on AtriCure (ATRC), despite Medtronic’s (MDT) limited US launch of a competing product to AtriCure’s AtriClip. Read more here.
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference
AtriCure Releases 2023 ESG Report
AtriCure GAAP EPS of -$0.20, revenue of $98.29M beats by $1.64M (NASDAQ:ATRC)
AtriCure's Q3 financial results exceed expectations with a beat on both EPS and revenue, showcasing strong performance and growth for the company.
AtriCure Reports Third Quarter 2023 Financial Results
AtriCure to Participate in the Stifel 2023 Healthcare Conference
Oversold Conditions For AtriCure (ATRC)
AtriCure to Announce Third Quarter 2023 Financial Results
Oversold Conditions For AtriCure (ATRC)
Despite a slower Q2, Needham sees medtech market growing 7% in 2023 (NYSE:BSX)
Needham sees the medtech sector growing by 7% in 2023 versus 5.7% last year, despite slowed growth in Q2, helped by double-digit growth in certain cardiology categories. Read more.
AtriCure Breaks Below 200-Day Moving Average - Notable for ATRC
(NASDAQ:ATRC)
AtriCure press release (ATRC): Q2 GAAP EPS of -$0.11 beats by $0.19.Revenue of $100.9M (+19.4% Y/Y) beats by $3.41M.
AtriCure Reports Second Quarter 2023 Financial Results
AtriCure to Participate at Upcoming Investor Conferences
Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023 (BBIO)
Acumen (ABOS), Establishment Labs (ESTA), Arcus (RCUS) and BridgeBio (BBIO) are four of BTIG's top picks for small and mid-cap healthcare stocks for 2H 2023. Read more here.
